This is also important because JAK2 inhibition, as a therapeutic modality for MPNs, does not greatly or reliably reduce the malignant clonal burden or extent of bone marrow fibrosis (68, 79, 80). This evidence concerns the gene JAK2 and primary myelofibrosis.